26th Apr 2016 05:40
LONDON (Alliance News) - AstraZeneca PLC late on Monday said the US Food & Drug Administration has approved Bevespi Aerosphere for treating sufferers of chronic obstructive pulmonary disease.
The product is a twice-daily, fixed-dose treatment and is the first product to be approved using the drugmaker's Co-Suspension technology, which allows the delivery of one or more different medicines from a single inhaler.
"LAMA/LABAs are emerging as a preferred treatment option for many COPD patients. This class aims to provide maximum bronchodilation, which enables patients to breathe better and may help them be more active," said Sean Bohen, executive vice-president of global medicines development and chief medical officer at AstraZeneca.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
Astrazeneca